A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Irlam, Joely J
Betts, Guy N J
Miller, Crispin J
West, Catharine M L
AffiliationTranslational Radiobiology Group, Institute of Cancer Sciences, University of Manchester, Christie Hospital, Manchester, United Kingdom.
MetadataShow full item record
AbstractTumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefit from hypoxia-modifying treatment in both cancer types.
CitationA 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. 2013, 19 (17):4879-88 Clin Cancer Res
JournalClinical Cancer Research